Clinical

This retrospective study and prospective follow-up provide insight into predictors of thrombotic episodes in patients with autoimmune hemolytic anemia (AIHA) and indicators that anticoagulant prophylaxis may be beneficial to certain patients.

Drs Kaddis and Oskouei define interchangeable biosimilars, their FDA requirements, and switching studies.

Atheer Kaddis, PharmD, and Sonia T. Oskouei, PharmD, BCMAS, DPLA, provide an overview of biosimilars and the preparation for future launches on the horizon.

Data presented at the American Society of Clinical Oncology annual meeting found non-White patients are less likely to receive immunotherapy for head and neck cancer, said Amila Patel, PharmD, chief clinical officer, Navigating Cancer.

Jim Januzzi, MD, outlines a multitude of drug treatment options for heart failure revolving around patient ejection fraction (EF) status.

A panel of medical experts open a discussion surrounding heart failure and its prevalence in health care.

The study also found broad tolerability, with 98% of patients remaining on the therapy after 12 months.

Authors explained how multiple myeloma emerges from earlier clinical phases and the tumor’s microenvironment in the early course of the disease plays a critical role in the survival of myeloma cells.

Clinical trials and targeted agents do not appear to affect health care–related quality of life, however.

Probability of continuous glucose monitoring device use was highest for patients with type 1 diabetes (T1D) in middle adulthood, decreasing as older age increased.

City of Hope has announced that a patient living with HIV, who received a stem cell transplant from an unrelated donor to treat acute myelogenous leukemia, has been in remission from both diseases since 2019.

Medication risk scores analyze an individual’s medication regimen to look for the potential for simultaneous, multi-drug interactions, which can cause adverse drug events and other medication-related harms.

The Institute for Clinical and Economic Review (ICER) released the report, which supports the long-term value of betibeglogene autotemcel (beti-cel) for the treatment of beta thalassemia.

A new case report highlights the difficulties in pinning down spinal muscular atrophy (SMA) when it presents in a mild form.

A new study highlights potential therapies to decrease cardiovascular risk in people with systemic lupus erythematosus (SLE) and identifies biomarkers that may indicate a heightened risk.

Overall, infections occurred in 18.42% of cases and typically occurred within the first month, significantly dropping from then on.

This prospective study on reflectance confocal microscopy, a high-resolution and noninvasive form of imaging for skin cancer, investigated if the diagnostic method could improve accuracy results by 30% following dermoscopy.

A patient who failed to respond to rituximab and steroids later saw dramatic improvement with sutimlimab

Dr Ciombor provides her insight on determining appropriate testing strategies for patients with metastatic colorectal cancer.

In his final thoughts, Dr Haumschild outlines opportunities for next-generation sequencing in treatment for metastatic colorectal cancer.

In retina surgery, obtaining prior authorization is an extra burden, and a delay in treatment for some of these patients could mean loss of vision, said Sabin Dang, MD, ophthalmologist with The Retina Institute.

The research may eventually help clinicians optimize therapy with immune checkpoint inhibitors.

Understanding that patients who are HER2-low are different from patients who are HER2-positive and -negative means having the right way to evaluate and identify these patients, explained Debra Patt, MD, PhD, MBA, executive vice president of Texas Oncology.

A recent survey of patients with urticarial vasculitis found that quality-of-life (QOL) impairment is an important factor to consider when putting disease management plans in place.

In this interview, Vernon Sondak, MD, the chair of the Department of Cutaneous Oncology at the H. Lee Moffitt Cancer Center and Research Institute in Florida, explains the latest approach to treating patients with melanoma with BRAF mutations, including those whose disease has spread to the brain or other sites.